Currently Available metastasized Kidney Cancer Treatment Options :
→ Votrient (pazopanib) (2009) New!!!
….. See Phase III clinical trial below
….. Cure Today
….. Doubts are expressed over drugs safety
→ Afinitor (everolimus) (2009)
….. Side Effects
….. Consumer Drug Information
….. Professional Information

→ Avastin (bevacizumab) with Interferon Alpha-2a (IFN) (2009)

(10/20/2009) – The FDA approved Votrient (pazopanib) today for the treatment of  kidney cancer. This makes the 3rd drug approved this year alone. Afinitor (March) and Avastin (May) were approved earlier this year.
Pazopanib was approved on placebo results alone. Further studies will be conducted to determine the full side effects associated with this drug.
This drug inhibits the growth of new blood vessels that feeds the tumor. Results have shown that this drug has a medium PFS (Progression Free Survival) from less than 3 months to just over 11 months.
Pazopanib has a …

Sutent ®
Generic Name: Sunitinib
Other Name: SU11248
(Sutent official information)
Drug Type:
Sutent is a targeted therapy and is a receptor protein-tyrosine kinase inhibitor.  It inhibits the actions of vascular endothelial growth factor (VEGF) and is an angiogenesis inhibitor.  

What Sutent Is Used For:

Treatment of gastrointestinal stromal tumor (GIST)
Treatment of advanced renal cell carcinoma

Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.
How Sutent Is Given:

As a capsule taken by mouth.
May be taken with or without food.  Avoid grapefruit juice. …

This is not recent news, however I found that there are number of advanced kidney cancer patients have never heard of it, and do not know that there is a new targeted cancer drug you may benefit from, if you did not respond to initial targeted therapy such as Sutent and Nexavar.
A new targeted drug which was studied in clinical trial at the Masonic Cancer Center, University of Minnesota has been approved by FDA on 30th of March 2009, studies showed that it may extend life for some patients with …

The treatment options for renal cell carcinoma depend on many factors, such as the  type of RCC, the tumor size, location, the general health state and age of the patient. One of the most important factors is the cancer STAGE. First, click this simplified stage form, you will need to know your cancer stage before continuing.
Stage I or stage II:
Patients with stage I and II RCC most often have their cancers surgically removed by either removes parts of the kidney or the entire kidney is called nephrectomy. Research shows that if the …

Many patients who are taking sutent ask questions about Sutent’s side-effects, such as mouth sores, vomiting, taste changes. I suggest all the patients who are taking this targeted cancer drug, read its instruction book, or go to Sutent official site to read the “About SUTENT” categories on the left of the web page. But of course, if you ask in some kidney cancer patients groups or forums, you may find better answers, for example, they may tell you to use Biotene to manage mouth sores, and “ask your nurse for the …

I just received the book i bought from ebay, named 100 Questions and Answers about Kidney Cancer, author is Steven C. Campbell, he is MD, PhD Professor of Surgery Section of Urological Oncology Glickman Urological Institute Cleveland Clinic Foundation Cleveland, he is also the author of another book named Renal Cell Carcinoma, but that book is too expensive, so maybe I will buy it sometime later.
I am writing an article called Top 10 Most Asked Questions About Renal Cell Carcinoma, I collect those questions people frequently asked about RCC from Internet, …

Research shows that the targeted cancer drug sunitinib (SUTENT) has shown promising results in advanced kidney cancer patients who have a poor prognosis. — HealthDay News (Thursday, July 16)
Previous clinical trials showed that sunitinib was effective in advanced kidney cancer patients, and according to background information with the study, the drug has been approved worldwide as a first and second line treatment for these patients. However, little is known about the activity of the drug in advanced kidney cancer patients with poor prognosis, such as those patients whose cancer has …